

RECEIVED
CENTRAL FAX CENTER 005/019

JUL 21 2006

CERTIFICATE OF MAILING
37 C.F.R. 1.8

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Isaiah J. Fidler

Corazon D. Bucana

Serial No.: 10/010,763

Filed: November 2, 2001

For: METHODS FOR DETECTING THE EFFICACY OF ANTICANCER TREATMENTS

Group Art Unit: 1642

Examiner: Ungar, Susan NMN

Atty. Dkt. No.: UTSC:684US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

07/25/2006 BABRAHAI 00000042 501212 10010763
01 FC:1806 180.00 DA


25511061.1

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed herewith. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/UTSC:684US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,


David L. Parker
Reg. No. 32,165
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: March 9, 2005

25511061.1

JUL 21 2006

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
 600 CONGRESS AVENUE, SUITE 2400
 AUSTIN, TEXAS 78701-2978
WWW.FULBRIGHT.COM

FACSIMILE TRANSMISSION**DATE:** July 21, 2006**MATTER NUMBER:** 01982 10110590

RECIPIENT(S):	FAX NO.:	PHONE NO.:
Examiner Susan Ungar, Ph.D. USPTO - Group Art 1642	571-273-8300	

FROM: David Parker **FLOOR:** 2001**PHONE:** (512) 536-3055 **FAX:** (512) 536-4598**RE:** Serial No. 10/010,763**NUMBER OF PAGES INCLUDING COVER PAGE:** 19**MESSAGE:****CAUTION - CONFIDENTIAL**

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU.

**IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL
 _____ AT _____ AS SOON AS POSSIBLE.**

RECEIVED
CENTRAL FAX CENTER

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-2978
WWW.FULBRIGHT.COM

JUL 21 2006

DAVID PARKER
PARTNER
DPARKER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3055
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

July 21, 2006

CERTIFICATE OF FACSIMILE TRANSMISSION
37 C.F.R. § 1.8

I hereby certify that this correspondence is being transmitted to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Attn: Examiner Ungar, GAU 1642, facsimile number (571) 273-8300 on the date below:

July 21, 2006
Date

David L. Parker

Examiner Susan Ungar, Ph.D.
United States Patent and Trademark Office
Group Art Unit 1642
P. O. Box 1450
Alexandria, VA 22313-1450

*Re: Serial Number 10/010,763 Entitled "METHODS FOR DETECTING THE EFFICACY OF ANTICANCER TREATMENTS" by Isaiah J. Fidler and Corazon D. Bucana
Our Ref. No. UTSC.684US*

Dear Examiner Ungar:

After reviewing each of the Office Actions and the Notice of Allowability, it has come to our attention that the Supplemental Information Disclosure Statement, Form PTO-1449 and A1-A3, C1-C7 and C19-C30 references submitted on February 7, 2002, the Supplemental Information Disclosure Statement, Form PTO-1449 and A4 and C31-C33 references submitted on July 24, 2002, and the Supplemental Information Disclosure Statement, Form PTO-1449 and C34-C38 references submitted on March 9, 2005, were apparently never signed off by an Examiner.

For your convenience we have enclosed a copy of each of the Supplemental Information Disclosure Statements and Form PTO-1449s that were filed with the Patent and Trademark Office (PTO) on 7 February 2002, 24 July 2002, and 9 March 2005, respectively. Also enclosed are copies of PTO stamped postcards indicating the documents submitted. The copies of the references previously submitted have not been enclosed. Please let us know if you would like us to resubmit those as well.

Please review and approve these Supplemental Information Disclosure Statements. If you need additional information, please let us know.

25677692.1

HOUSTON • NEW YORK • WASHINGTON DC • AUSTIN • DALLAS • LOS ANGELES • MINNEAPOLIS • SAN ANTONIO
DUBAI • HONG KONG • LONDON • MUNICH • RIYADH

Examiner Susan Ungar, Ph.D.

July 21, 2006

Page 2

Thank you for your assistance in this matter.

Very truly yours,
S
David L. Parker

DLP/jch
Enclosures

25677692.1

Please indicate receipt of the below-identified paper:

<input type="checkbox"/> New Application For:	Priority Date:		
<input type="checkbox"/> Foreign priority already claimed			
<input type="checkbox"/> Continuation	<input type="checkbox"/> CIP	<input type="checkbox"/> Divisional	CPA <input type="checkbox"/>
<input type="checkbox"/> Specification:	Pages	<input type="checkbox"/> Drawings:	Sheets
<input type="checkbox"/> Response to Office Action Dated: 11/19/04		<input type="checkbox"/> Final Rejection	
<input checked="" type="checkbox"/> Other: Request for Extension of Time; Supplemental IDS (w/i 1449 and refs. C34-C38); \$235 check; transmittal letter			
<input type="checkbox"/> Assignment Enclosed	<input checked="" type="checkbox"/> Cert. of Timely Mailing	<input type="checkbox"/> Exp. Mktg.	P E JC 84
<u>IDENTIFICATION OF APPLICATION</u>			
Serial No.:	10/010,763		
Title: Methods for Detecting the Efficacy of Anticancer Treatments			
Applicant: Fidler et al.	Attorney: BENTZ BENTZ		
Client: M. D. Anderson Cancer Center	F&J File No.: UTSC:684US		
Mailed: 3/9/05	Due Date: 2/9/05		



Page 1 of 1

Form PTO-1449 (modified)		Atty. Docket No. UTSC:684US	Serial No. 10/010,763
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Isaiah J. Fidler Corazon D. Bucana	
		Filing Date: November 2, 2001	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C34	Pollack et al. "Therapy of human carcinomas in athymic mice by inhibition of egf receptor-mediated signal transduction with cp-358774: dynamics of receptor inhibition and anti-tumor effects," <i>Proc Annu Meet Am Assoc Cancer Res</i> , Abstract 4249, 1997.
	C35	Pollack et al., "Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with cp-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice," <i>JPET</i> , 291739-748, 1999.
	C36	Prewett et al., "Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 Inhibits the growth of human renal cell carcinoma xenografts in nude mice," <i>Clinical Cancer Research</i> , 4:2957-2966, 1998.
	C37	Prewett et al., "The biologic effects of C225, a chimeric monoclonal antibody to the egfr, on human prostate carcinoma," <i>J of Immunotherapy</i> , 19:419-427, 1997.
	C38	Scardino and Wheeler, "Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy," <i>NCI Monogr</i> , 7:95-103, 1988.

25511056.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

UW

Please indicate receipt of the below-identified paper:

<input type="checkbox"/> New Application For:	Priority Date:		
<input type="checkbox"/> Foreign priority already claimed			
<input type="checkbox"/> Continuation	<input type="checkbox"/> CIP	<input type="checkbox"/> Divisional	CPA <input type="checkbox"/>
<input type="checkbox"/> Specification:	Pages	<input type="checkbox"/> Drawings:	Sheets
<input type="checkbox"/> Response to Office Action Dated: <input type="checkbox"/> Final Rejection			
<input checked="" type="checkbox"/> Other: SIDS; Form PTO-1449; References (A4, C31-C33); trans. Itc.; postcard			
<input type="checkbox"/> Assignment Enclosed	<input checked="" type="checkbox"/> Cert. of Timely Mailing	<input type="checkbox"/> Exp. Mar. 1, 2011	<input type="checkbox"/> Exp. Mar. 1, 2011
<u>IDENTIFICATION OF APPLICATION</u>			
Serial No.:	10/010,763		
Title:	METHODS FOR DETECTING THE EFFICACY OF ANTICANCER TREATMENTS		
Applicant: Isaiah J. Fidler and Corazon D. Bucana		Attorney: SLH	
Client: UTSC		F&J File No.: UTSC:684US	
Mailed: July 24, 2002	Filed:	Due Date:	

PATENT & TRADEMARK OFFICE
MAY 3 2001

P E

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
 600 CONGRESS AVENUE, SUITE 2400
 AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
 PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
 TELEPHONE: (512) 474-5201
 FACSIMILE: (512) 536-4598

July 24, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
<p>I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:</p>	
<u>July 24, 2002</u>	_____ Date
 <u>Steven L. Highlander</u>	

Commissioner for Patents
 Washington, DC 20231

Re: *U.S. Patent Application No. 10/010,763 entitled "METHODS FOR DETECTING THE EFFICACY OF ANTICANCER TREATMENTS" by Isaiah J. Fidler and Corazon D. Bucana*
Our Reference: UTSC:684US
Client Reference: MDA00-053


Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (A4, C31-C33).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:684US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


 Steven L. Highlander
 Reg. No. 37,642

SLH/cmb
 Encl.: as noted
 25189805.1

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****In re Application of:**Isaiah J. Fidler
Corazon D. Bucana

Serial No.: 10/010,763

Filed: November 2, 2001

For: METHODS FOR DETECTING THE
EFFICACY OF ANTICANCER
TREATMENTS

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSC:684US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

July 24, 2002

Data

Steven L. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTCommissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

25189802.1

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:684US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: July 24, 2002

25189802.1

PAGE 11/19 * RCVD AT 7/21/2006 4:44:59 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/20 * DNIS:2738300 * CSID:512 536 4598 * DURATION (mm:ss):04:08

Page 1 of 1

Form PTO-1449 (modified)		Atty. Docket No. UTSC:684US	Serial No. 10/010,763
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Isaiah J. Fidler Corazon D. Bucana	
		Filing Date: November 2, 2001	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A4	5,480,968	1/2/96	Kraus <i>et al.</i>	530	326	11/10/92

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C31	Albanell <i>et al.</i> , 'Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zld1839 ('Iressa') in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition,' <i>European Journal of Cancer</i> , 37(Supp. 6): S159, 2001.
	C32	Parker <i>et al.</i> , 'Preferential activation of the epidermal growth factor receptor in human colon carcinoma liver metastases in nude mice,' <i>J. of Histochemistry and Cytochemistry</i> , 46(5):595-602, 1998.
	C33	Pollack <i>et al.</i> , 'Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice,' <i>J. Pharmacology and Experimental Therapeutics</i> , 291(2):739-748, 1999.

25189785.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Please indicate receipt of the below-identified paper:

<input type="checkbox"/> New Application For:	Priority Date:		
<input type="checkbox"/> Foreign priority already claimed			
<input type="checkbox"/> Continuation	<input type="checkbox"/> CIP	<input type="checkbox"/> Divisional	<input type="checkbox"/> CPA
<input type="checkbox"/> Specification:	Pages	<input type="checkbox"/> Drawings:	Sheets
<input type="checkbox"/> Response to Office Action Dated:	<input type="checkbox"/> Final Rejection		
<input checked="" type="checkbox"/> Other: IDS; Form PTO-1449; References (A1-A3, C1-C30); Transmittal letter; Postcard			
<input type="checkbox"/> Assignment Enclosed	<input checked="" type="checkbox"/> Cert. of Timely Mailing	<input type="checkbox"/> Exp. Mail:	

IDENTIFICATION OF APPLICATION

Serial No.:	10/010,763
Title:	METHODS FOR DETECTING THE EFFICACY OF ANTICANCER TREATMENTS
Applicant:	Isaiah J. Fidler and Corazon D. Bucana
Client:	UT MD Anderson Cancer Center
Mailed:	February 7, 2002
Filed:	
Attorney:	SLH
F&J File No.:	UTSC:684US
Due Date:	

07/21/2006 15:50 FAX 512 536 4598

FULBRIGHT & JAWORSKI

RECEIVED
CENTRAL FAX CENTER

014/019

JUL 21 2006

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

STEVEN L. HIGHLANDER
PARTNER

INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

February 7, 2002

FILE: UTSC:684US

CERTIFICATE OF MAILING 37 C.F.R. 1.6	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
February 7, 2002	_____ Date Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

RE: *SN 10/010,763 "METHODS FOR DETECTING THE EFFICACY OF ANTICANCER TREATMENTS" – Isaiah J. Fidler and Corazon D. Bucana*
(Client Reference: MDA00-053)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1-A3, C1-C30).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10110590/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/cmb

Encl: as noted

25122245.1

JUL 21 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Isaiah J. Fidler
Corazon D. Bucana

Serial No.: 10/010,763

Filed: November 2, 2001

For: METHODS FOR DETECTING THE
EFFICACY OF ANTICANCER
TREATMENTS

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSC:684US/SLH

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
February 7, 2002	Date
_____ Steven A. Highlander	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

25122239.1

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10110590/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 7, 2002

25122239.1

Page 1 of 3

Form PTO-1449 (modified)		Atty. Docket No. UTSC:684US/SLH	Serial No. 10/010,763
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Isaiah J. Fidler Corazon D. Bucana	
		Filing Date: November 2, 2001	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,340,744	8/23/94	Lavker <i>et al.</i>	436	63	10/12/93
	A2	5,427,916	6/27/95	Gewirtz <i>et al.</i>	435	6	8/10/94
	A3	5,599,681	2/4/97	Epstein <i>et al.</i>	435	7.23	10/13/94

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Akiyama <i>et al.</i> , "Growth factor and growth factor receptor localization in the hair follicle bulge and associated tissue in human fetus," <i>J. Invest. Dermatol.</i> , 106(3):391-396, 1996.
	C2	Bergler <i>et al.</i> , "The expression of epidermal growth factor receptors in the oral mucosa of patients with oral cancer," <i>Arch. Otorhinolaryngol.</i> , 246(3):121-125, 1989.
	C3	Bergmann <i>et al.</i> , "Insulin-like growth factor I overexpression in human pancreatic cancer. evidence for autocrine and paracrine roles," <i>Cancer Res.</i> , 55:2007-2011, 1995.
	C4	Bruns <i>et al.</i> , "Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma," <i>Cancer Res.</i> , 60:2926-2935, 2000.
	C5	Bruns <i>et al.</i> , "In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice," <i>Neoplasia</i> , 1:50-62, 1999.
	C6	Chan <i>et al.</i> , "A common human skin tumour is caused by activating mutations in β -catenin," <i>Nat. Genet.</i> , 21:410-413, 1999.
	C7	Ciardiello <i>et al.</i> , "Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A," <i>J. Nat'l Cancer Inst.</i> , 88:1770-1776, 1996.

25111125.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Page 2 of 3

Form PTO-1449 (modified)		Atty. Docket No. UTSC:684US/SLH	Serial No. 10/010,763
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Isaiah J. Fidler Corazon D. Bucana	
		Filing Date: November 2, 2001	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C8	Gill <i>et al.</i> , "Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity," <i>J. Biol. Chem.</i> , 259:7755-7760, 1984.
	C9	Green and Couchman, "Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition," <i>J. Invest. Dermatol.</i> , 85(3):239-245, 1985.
	C10	Green and Couchman, "Distribution of epidermal growth factor receptors in rat tissues during embryonic skin development, hair formation, and the adult hair growth cycle," <i>J. Invest. Dermatol.</i> , 83(2):118-123, 1984.
	C11	Green <i>et al.</i> , "Distribution and number of epidermal growth factor receptors in skin is related to epithelial cell growth," <i>Dev. Biol.</i> , 100:506-512, 1983.
	C12	Hansen <i>et al.</i> , "Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development," <i>Am. J. Pathol.</i> , 150(6):1959-1975, 1997.
	C13	Harmon <i>et al.</i> , "Bisindolylmaleimide protein-kinase-C inhibitors delay the decline in DNA synthesis in mouse hair follicle organ cultures," <i>Skin Pharmacol.</i> , 10:71-78, 1997.
	C14	Korc <i>et al.</i> , "Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha," <i>J. Clin. Invest.</i> , 90:1352-1360, 1993.
	C15	Lokshin <i>et al.</i> , "Mechanisms of growth stimulation by suramin in non-small-cell lung cancer cell lines," <i>Cancer Chemother Pharmacol.</i> , 43:341-347, 1999.
	C16	Luetke <i>et al.</i> , "The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase," <i>Genes Dev.</i> , 8:399-413, 1994.
	C17	Maiorano and Favia, "Expression of phosphotyrosine in squamous cell carcinoma of the oral mucosa. Preliminary study," <i>Boll. Soc. Ital. Biol. Sper.</i> , 71(5-6):157-162, 1995.
	C18	Maiorano <i>et al.</i> , "Prognostic implications of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa," <i>J. Pathol.</i> , 185:167-174, 1998.

25111125.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Page 3 of 3

Form PTO-1449 (modified)		Atty. Docket No. UTSC:684US/SLH	Serial No. 10/010,763
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Isaiah J. Fidler Corazon D. Bucana	
		Filing Date: November 2, 2001	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C19	Murillas <i>et al.</i> , "Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure," <i>EMBO J.</i> , 14(21):5216-5223, 1995.
	C20	Nameda <i>et al.</i> , "Endotoxin-induced L-arginine pathway produces nitric oxide and modulates the Ca ²⁺ activated K ⁺ channel in cultured human dermal papilla cells," <i>J. Invest Dermatol.</i> , 106:342-345, 1996.
	C21	Saleh <i>et al.</i> , "Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation," <i>Cancer Biother. Radiopharm.</i> , 14:451-463, 1999.
	C22	Smythe <i>et al.</i> , "The activity of HMG-CoA reductase and acetyl-CoA carboxylase in human apocrine sweat glands, sebaceous glands, and hair follicles is regulated by phosphorylation and by exogenous cholesterol," <i>J. Invest. Dermatol.</i> , 111:139-148, 1998.
	C23	van Oijen <i>et al.</i> , "Increased expression of epidermal growth factor receptor in normal epithelium adjacent to head and neck carcinomas independent of tobacco and alcohol abuse," <i>Oral Dis.</i> , 4(1):4-8, 1998.
	C24	Wagner <i>et al.</i> , "Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth <i>in vitro</i> and <i>in vivo</i> ," <i>Gastroenterology</i> , 114:798-807, 1998.
	C25	Wang <i>et al.</i> , "Effects of <i>in vivo</i> treatments of nicotine and benzo[a]pyrene on the epidermal growth factor receptor in hamster buccal pouch," <i>Toxicology</i> , 107:31-38, 1996.
	C26	Wang <i>et al.</i> , "Identification of epidermal growth factor receptor in human buccal mucosa," <i>Arch. Oral Biol.</i> , 35(10):823-828, 1990.
	C27	Whitcomb <i>et al.</i> , "Immunohistochemical mapping of epidermal growth-factor receptors in normal human oral soft tissue," <i>Arch. Oral Biol.</i> , 38(9):823-826, 1993.
	C28	Yamada <i>et al.</i> , "Evaluation of epidermal growth factor receptor in squamous cell carcinoma of the oral cavity," <i>Oral Surg. Oral Med. Oral Pathol.</i> , 73:67-70, 1992.
	C29	Yamanaka <i>et al.</i> , "Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness," <i>Anticancer Res.</i> , 13:565-569, 1993.
	C30	Yamanaka <i>et al.</i> , "Overexpression of HER2/neu oncogene in human pancreatic carcinoma," <i>Hum. Pathol.</i> , 24:1127-1134, 1993.

25111125.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)